TMRW Life Sciences

Founded in 2018 and based in New York, TMRW Life Sciences, Inc. is a femtech company that develops TMRW ivfOS, an integrated platform which uses radio-frequency identification for preserving, managing, identifying, and storing fertility cells in cryo-temperature. The company was co-founded by Alan Murray, Jeffrey Port, and Joshua Abram. TMRW is now being used by fertility clinics in the United States, including Vios Fertility Institute, Conceptions Reproductive Associates of Colorado, San Diego Fertility Center, Boston IVF, and Colorado Center for Reproductive Medicine (CCRM)., a portfolio company of FIOS Capital, Transformation Capital, Casdin Capital, GV, 5AM Ventures and AWM Investment Company, merged into ReproTech LLC, a portfolio company of Red Barn Equity Partners. Financial terms were not disclosed. TMRW Life Sciences provides an automated platform for the management, identification, and storage of frozen human eggs and embryos at the center of every IVF procedure. The company replaces the current analog system with integrated software and robotics, 24/7 remote monitoring, and a complete digital chain of custody for all frozen eggs and embryos in the IVF lab. TMRW’s software eliminates error-prone manual tasks in the lab that put specimens at risk, allowing embryologists to focus on the more skilled and technical aspects of their work. TMRW Life Sciences plans to accelerate its global expansion, advance cutting-edge product innovation, develop consumer awareness of the platform, and support future business development opportunities.

1. Series D

   Jun 28, 2024

   Amount

   $28M

   Investors

   Locked

2. Series C

   Jul 20, 2021

   Amount

   Undisclosed

   Investors

   Locked

3. Series B

   Dec 17, 2019

   Amount

   $25M

   Investors

   Locked

4. Series A

   Nov 30, 2018

   Amount

   $12M

   Investors

   Locked